Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Jason T. Olin"'
Publikováno v:
Journal of the American Podiatric Medical Association. 104:479-485
BackgroundEfinaconazole 10% solution is a new triazole antifungal agent developed for the topical treatment of onychomycosis. This article reviews the pooled results of the two pivotal clinical trials of this drug that have been performed in the Unit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdc5ad99b458556c16af5683b75d970d
https://doi.org/10.7547/0003-0538-104.5.479
https://doi.org/10.7547/0003-0538-104.5.479
Publikováno v:
International Journal of Clinical Practice. 65:465-471
Summary Aim: The cholinesterase inhibitor rivastigmine is available in both oral and transdermal forms. The efficacy of oral rivastigmine appears to be dose-dependent. The current analysis investigates the effect of dose on the efficacy of the rivast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6a1fa685d65a84dd3d0bfcd8f8e5859
https://doi.org/10.1111/j.1742-1241.2011.02641.x
https://doi.org/10.1111/j.1742-1241.2011.02641.x
Publikováno v:
American Journal of Alzheimer's Disease & Other Dementiasr. 26:65-71
Background: Rivastigmine patches provide similar efficacy to rivastigmine capsules with a lower incidence of gastrointestinal side effects in patients with probable Alzheimer’s disease (AD). Methods: Post hoc analysis of a 24-week, prospective, int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::785798d0c06b8eeadbe48299da52e7c3
https://doi.org/10.1177/1533317510391240
https://doi.org/10.1177/1533317510391240
Publikováno v:
International Journal of Geriatric Psychiatry. 26:1236-1243
Objectives The cholinesterase inhibitor rivastigmine is approved for the symptomatic treatment of mild to moderate Alzheimer's disease (AD). This exploratory, hypothesis-forming analysis assessed response to rivastigmine according to severity of deme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8fa3244b4ce00302bd407eb1d6e0bbc
https://doi.org/10.1002/gps.2669
https://doi.org/10.1002/gps.2669
Publikováno v:
American Journal of Alzheimer's Disease & Other Dementiasr. 25:627-633
Alzheimer’s disease (AD) patients treated with rivastigmine transdermal patch have shown statistically significant differences versus placebo on the AD Assessment scale-cognitive subscale (ADAS-cog). In this retrospective analysis of a double-blind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1310c53c9529b34ac5cb5c0bd5631fb7
https://doi.org/10.1177/1533317510385808
https://doi.org/10.1177/1533317510385808
Publikováno v:
CNS Neuroscience & Therapeutics. 16:330-336
SUMMARY Background and objective: Rivastigmine is approved in the USA for the treatment of mild to moderate Alzheimer's disease and Parkinson's disease dementia (PDD). Executive function (EF) deficits are a core symptom of PDD. The current objective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ff80db36c197bb5ef65745850dc8702
https://doi.org/10.1111/j.1755-5949.2010.00182.x
https://doi.org/10.1111/j.1755-5949.2010.00182.x
Publikováno v:
CNS Spectrums. 15:594-598
Background: Investigate the safety and tolerability of rivastigmine capsules and transdermal patch in patients with moderate Alzheimer's disease receiving concomitant memantine.Methods: Safety data from two prospective, open-label, multicenter trials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2e6d2e28807391f93f81fdad6ca1bb2
https://doi.org/10.1017/s1092852900000572
https://doi.org/10.1017/s1092852900000572
Autor:
Frederick A. Schmitt, Sibel Tekin, Kolbjørn Brønnick, Dag Aarsland, Xiangyi Meng, Jason T. Olin
Publikováno v:
American Journal of Alzheimer's Disease & Other Dementiasr. 25:407-413
Rivastigmine has been shown to improve cognition in patients with Parkinson’s disease dementia (PDD). To further explore the impact of anticholinesterase therapy on PDD, Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) items wer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4436415208d78df86249df85898dc86
https://doi.org/10.1177/1533317510367486
https://doi.org/10.1177/1533317510367486
Publikováno v:
International Journal of Clinical Practice. 64:651-660
Today patients with mild to moderate Alzhiemer's disease (AD) have a treatment approach choice: oral or transdermal delivery. The aim of this review was to provide a concise, comprehensive overview of the clinically relevant safety, tolerability and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2059a7489806c64592ef5193023cb3e7
https://doi.org/10.1111/j.1742-1241.2009.02330.x
https://doi.org/10.1111/j.1742-1241.2009.02330.x
Publikováno v:
Dementia and Geriatric Cognitive Disorders. 29:510-515
Aims: To investigate the effects of rivastigmine capsule 3–12 mg/day over 24 weeks on activities of daily living (ADLs) in patients with dementia associated with Parkinson’s disease (PDD). Methods: Post hocanalysis of a prospective, multicenter,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd0f9c1c83a03f140327f4eddf724236
https://doi.org/10.1159/000305100
https://doi.org/10.1159/000305100